Fusion Antibodies plc (LSE:FAB) has released its unaudited financial results for the first half of fiscal 2026, reporting lower revenues compared with the same period last year but noting an improvement relative to the second half of 2025. Enhanced gross margins indicate greater operational efficiency. A notable development during the period was the granting of a U.S. patent for its OptiMAL® library design, marking a significant step forward for the company’s intellectual property strategy.
The company also advanced its partnership with the National Cancer Institute, which plans to use the OptiMAL® platform in upcoming projects. Additionally, Fusion secured new business, including a stable cell line development agreement with a U.S. biotechnology firm and several antibody humanization contracts, further reinforcing its market position. Looking ahead, management expects stronger results in the second half of the year, supported by a healthy order pipeline and the planned December launch of OptiMAL®.
The financial outlook remains weighed down by ongoing losses and cash flow challenges. While some technical indicators point to an improving trend, negative valuation metrics continue to pose headwinds. The absence of earnings call details and corporate event updates limits further forward-looking clarity.
About Fusion Antibodies
Founded in 2001 as a spin-out from Queen’s University Belfast, Fusion Antibodies is a Belfast-based contract research organization specializing in antibody engineering for therapeutic and diagnostic uses. Its services span antibody generation, development, production, characterization, and optimization. With a global client base that includes eight of the world’s top ten pharmaceutical companies, the firm focuses on accelerating drug development through advanced technologies and scientific innovation.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.
Leave a Reply